Detalles de la búsqueda
1.
Conflict of interest policies at Australian medical schools.
Intern Med J
; 54(1): 62-73, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37255333
2.
Factors relating to nonpublication and publication bias in clinical trials in Canada: A qualitative interview study.
Br J Clin Pharmacol
; 89(3): 1198-1206, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36268743
3.
Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review.
Br J Cancer
; 126(1): 144-161, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34599297
4.
Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis.
J Gen Intern Med
; 37(2): 290-297, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037923
5.
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings.
Br J Clin Pharmacol
; 88(2): 713-722, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34337777
6.
Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
Pharmacoepidemiol Drug Saf
; 31(10): 1039-1045, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790047
7.
"There are ways drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence.
Br J Clin Pharmacol
; 87(5): 2341-2353, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33129226
8.
Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly available disclosures.
Intern Med J
; 51(11): 1816-1824, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744396
9.
Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab.
Br J Clin Pharmacol
; 86(7): 1416-1429, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32067255
10.
A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
Pharmacoepidemiol Drug Saf
; 29(9): 1054-1063, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32696556
11.
Correction to: Medical, pharmacy and nursing students in the Baltic countries: interactions with the pharmaceutical and medical device industries.
BMC Med Educ
; 20(1): 122, 2020 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32321504
12.
Medical, pharmacy and nursing students in the Baltic countries: interactions with the pharmaceutical and medical device industries.
BMC Med Educ
; 20(1): 105, 2020 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252743
13.
Pharmaceutical company payments to Australian doctors reported to Medicines Australia, 2019-22: a cross-sectional analysis.
Med J Aust
; 220(8): 425-427, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38623760
14.
Secret safety warnings on medicines: A case study of information access requests.
Pharmacoepidemiol Drug Saf
; 28(4): 551-555, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30840349
15.
Medicines Information and the Regulation of the Promotion of Pharmaceuticals.
Sci Eng Ethics
; 25(4): 1167-1192, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29721844
16.
Mental Health Messages in Prominent Mental Health Apps.
Ann Fam Med
; 16(4): 338-342, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29987082
17.
Pharmaceutical company sponsorship of doctors: is gender equity a concern?
Med J Aust
; 219(6): 261-262, 2023 09 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37605943
18.
Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards.
BMC Public Health
; 18(1): 1322, 2018 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30486803
19.
Australian Clinical Trial Authors' Declarations of Industry Ties.
J Gen Intern Med
; 37(12): 3196-3198, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35257257
20.
Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?
Br J Clin Pharmacol
; 83(11): 2549-2556, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664660